holistik papdi by prof dr.jose rosma
DESCRIPTION
Holistik papdi prof dr.jose rosma PIT VII IDI Kota Bogor, 1-2 November 2014TRANSCRIPT
![Page 1: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/1.jpg)
The Moral of the Tale
As long as we reach the objective BP below 140/90 (130/80), it doesn’t matter how we get there
![Page 2: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/2.jpg)
ALLHAT (JAMA 2002)
“The key message from ALLHAT is that what matters most is getting blood pressure controlled’’
![Page 3: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/3.jpg)
A synergy in Mechanism of Action
3Ferrari R. Optimizing the treatment of hypertension and stable coronary artery disease:
clinical evidence for fixed-combination perindopril/amlodipine. Curr Med Res Opin. 2008;24:3543-3557.
ACE Inhibitor
Perindopril
Induction of relaxation
= Vasodilation
CCB
Amlodipine
Prevention of constriction
= Vasodilation
![Page 4: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/4.jpg)
ESHESC Recommendations for Combining BP-lowering Drugs
Mancia et al. European Heart Journal 2013:1-72
PROGRESS
ADVANCE
HYVET
FEVER
ELSA
VALUE
LIFE
SCOPE
ACCOMPLISH
ASCOT
INVEST
“Until now, no outcome study has been
conducted using the combination of
an angiotensin receptor antagonist
with a calcium antagonist.”
![Page 5: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/5.jpg)
![Page 6: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/6.jpg)
ACCOMPLISH: A Novel Hypertension Trial
• Traditional approach to hypertension management:
– Initiate monotherapy then sequentially add medications to achieve target BP
• ACCOMPLISH:
– Initiate single tablet combination therapy in high-risk hypertension
– Specific combinations may confer target organ protection in addition to their BP-lowering effects
![Page 7: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/7.jpg)
Kaplan Meier for Primary EndpointC
um
ula
tive e
vent
rate
HR (95% CI): 0.80 (0.72, 0.90)
20% Risk Reduction
Time to 1st CV morbidity/mortality (days)
p = 0
ACEI / HCTZ
CCB / ACEI650
526
.0002
INTERIM RESULTS Mar 08
![Page 8: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/8.jpg)
B.Dahlof (Co-chair), P.Sever (Co-chair), N. Poulter (Secretary)
H. Wedel (Statistician), G. Beevers, M. Caulfield, R. Collins
S. Kjeldsen, A. Kristinsson, J. Mehlsen, G. McInnes, M. Nieminen
E. O’Brien, J. Östergren, on behalf of the ASCOT Investigators
A randomised controlled trial of the prevention of CHD and other vascular events by BP and cholesterol lowering in a factorial
study design
![Page 9: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/9.jpg)
![Page 10: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/10.jpg)
![Page 11: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/11.jpg)
• Different components of antihypertensive efficacy have an
independent predictive value
1. Ohkubo DT, et al. The Ohasama study. J Hypertens. 2000;18:847–854. 2. Yamamoto Y, et al. Stroke. 1998; 29:570–576.
3. Ohkubo T et al. J Hypertens. 2002;20:2183–2189. 4. Stanton A, et al. Blood Press. 1993;2:289–295. 5. Pedersen OL? et
al. VALUE trial group. J Hypertens. 2007; 25:707–712.
Anti-Hypertensive Efficacy
Antihypertensive
Efficacy
Brachial
BP
Central
BP
BP
Variablilty
Nocturnal
BP
![Page 12: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/12.jpg)
12
Early & Strong BP Reduction
Bahl UK. Fixed dose perindopril and amlodipine in moderate-to-severe hypertension. 14th World Congress of Heart Disease 2008, Toronto, Canada.
Perindopril+Amlodipine
n= 1 250> 160mmHg
n= 161> 180mmHg
![Page 13: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/13.jpg)
• Different components of antihypertensive efficacy have an
independent predictive value
Antihypertensive Efficacy
Antihypertensive
Efficacy
Brachial
BP
Central
BP
BP
Variablilty
Nocturnal
BP
1. Ohkubo DT, et al. The Ohasama study. J Hypertens. 2000;18:847–854. 2. Yamamoto Y, et al. Stroke. 1998; 29:570–576.
3. Ohkubo T et al. J Hypertens. 2002;20:2183–2189. 4. Stanton A, et al. Blood Press. 1993;2:289–295. 5. Pedersen OL? et
al. VALUE trial group. J Hypertens. 2007; 25:707–712.
![Page 14: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/14.jpg)
![Page 15: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/15.jpg)
Perindopril-Amlodipine : Superior night-time SBP control
Better night-time BP control is
related to better survival rates
Dolan E et al; on behalf of the ASCOT Investigators. J Hypertens. 2009,27:876–885.
AMBP
![Page 16: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/16.jpg)
• Different components of antihypertensive efficacy have an
independent predictive value
Antihypertensive Efficacy
Antihypertensive
Efficacy
Brachial
BP
Central
BP
BP
Variablilty
Nocturnal
BP
1. Ohkubo DT, et al. The Ohasama study. J Hypertens. 2000;18:847–854. 2. Yamamoto Y, et al. Stroke. 1998; 29:570–576.
3. Ohkubo T et al. J Hypertens. 2002;20:2183–2189. 4. Stanton A, et al. Blood Press. 1993;2:289–295. 5. Pedersen OL? et
al. VALUE trial group. J Hypertens. 2007; 25:707–712.
![Page 17: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/17.jpg)
![Page 18: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/18.jpg)
Williams B. Circulation. 2006;113:1213-1225.
140
135
130
125
120
(mm
Hg
)
0 1 2 3 4 5 6 Years
Brachial SBP:∆ 0.7 mmHgP=0.07
Central SBP:∆ 4.3 mmHg P<0.0001
Amlodipine/Perindopril (n=1042) -blocker/diuretic (n=1031)
Amlodipine/perindopril combination significantly reduces central blood pressure
115
![Page 19: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/19.jpg)
• Different components of antihypertensive efficacy have an
independent predictive value
1. Ohkubo DT, et al. The Ohasama study. J Hypertens. 2000;18:847–854. 2. Yamamoto Y, et al. Stroke. 1998; 29:570–576.
3. Ohkubo T et al. J Hypertens. 2002;20:2183–2189. 4. Stanton A, et al. Blood Press. 1993;2:289–295. 5. Pedersen OL? et
al. VALUE trial group. J Hypertens. 2007; 25:707–712.
Anti-Hypertensive Efficacy
Antihypertensive
Efficacy
Brachial
BP
Central
BP
BP
Variablilty
Nocturnal
BP
![Page 20: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/20.jpg)
20
Stabilizes blood pressure to avoid excessive BP variability 1,2
BP variability: main cause of CV events.3
1.Rothwell PM et al. Lancet Neurol. 2010;9(5):469-480 2. Rothwell PM et al. Lancet. 2010;375:938-948.
3. Rothwell PM et al. Lancet. 2010;375:895–905.
/Perindopril
![Page 21: Holistik papdi by prof dr.jose rosma](https://reader031.vdocuments.site/reader031/viewer/2022020101/559b5c7c1a28abc27f8b4763/html5/thumbnails/21.jpg)
Perindopril-Amlodipine provides key organ protection
Perindopril/Amlodipine also
provides :
- a 30% reduction in the
new onset of diabetes and
- a 35% reduction in
peripheral arterial disease.
Dahlöf B et al. Lancet. 2005:366;895-906.